Study of KCNJ11 rs5219 Gene Polymorphism on the Efficacy of Metformin Combined with Gliclazide in Newly Diagnosed Diabetes Mellitus Type 2 Patients
OBJECTIVE To explore the effect of the polymorphisms of ATM(rs11212617),KCNJ11(rs5219),CYP2C9(rsl799853,rs1057910),TCF7L2(rs12255372,rs290487)and IRS1(rs1801278)on efficacy of metformin and gliclazide combined treatment for diabetes mellitus type 2.METHODS Eighty-one patients with newly diagnosed diabetes mellitus type 2 in Standardized Metabolic Disease Management Center of the Endocrinology Department of of Zhejiang Chinese Medical University Affiliated Jiaxing TCM Hospital were enrolled in this study,and they were treated with metformin hydrochloride tablets and gliclazide modified release tablets.MassARRAY was used to type the above single nucleotide polymorphism(SNP),and followed up for 3 months.Fasting plasma glucose(FPG),glycosylated hemoglobin type Alc(HbAlc)and fasting insulin(FINS)were compared before and after treatment.RESULTS The gene frequencies of all SNPs were compliant to Hardy-Weinberg equilibrium,the samples were well represented.The rs1 799853,rs 1057910,rs12255372 and rs1801278 had low mutation frequencies with poor clinical significance.The benefits of FPG compliance rate,increase of FINS,decrease of HbAlc after treatment were stronger in patients with homozygous rs5219 C allele than those with T-allele carriers(P＜0.05).However,there were no significant differences in treatment effects among the genotypes of rs1 1212617 and rs290487.CONCLUSION The rs5219 polymorphism of KCNJ11 gene is associated with the efficacy of metformin hydrochloride tablets and gliclazide modified release tablets in treating diabetes mellitus type 2,with a more significant effect observed in individuals homozygous for the C allele.This finding can serve as a reference for personalized medication in clinical treatment of diabetes mellitus type 2.
diabetes mellitus type 2MassARRAYsingle nucleotide polymorphismKCNJ11rs5219
NETL
NSTL
万方数据
维普
